Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

26.4%

14 terminated/withdrawn out of 53 trials

Success Rate

61.1%

-25.4% vs industry average

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

91%

20 of 22 completed trials have results

Key Signals

11 recruiting20 with results11 terminated

Enrollment Performance

Analytics

Phase 1

27(51.9%)

Phase 2

16(30.8%)

Phase 3

9(17.3%)

52Total

Phase 1(27)

Phase 2(16)

Phase 3(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials

NCT06880770Phase 3Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Role: lead

NCT07662096Phase 1Recruiting

A First-In-Human Study of ARO-033 in Adult Participants

Role: lead

NCT06347003Phase 3Active Not Recruiting

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Role: lead

NCT06822790Phase 3Recruiting

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Role: lead

NCT07223658Phase 1Recruiting

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Role: lead

NCT06937203Phase 1Recruiting

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Role: lead

NCT06672445Phase 1Active Not Recruiting

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Role: lead

NCT06700538Phase 1Recruiting

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Role: lead

NCT06347133Phase 3Active Not Recruiting

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Role: lead

NCT07241546Phase 2Recruiting

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Role: lead

NCT07221344Phase 1Recruiting

Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Role: lead

NCT05217667Phase 2Terminated

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Role: lead

NCT07037771Phase 3Recruiting

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Role: lead

NCT05089084Phase 3Completed

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Role: lead

NCT07473843Phase 3Not Yet Recruiting

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Role: lead

NCT05083364Phase 1Completed

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Role: lead

NCT06209177Phase 1Completed

Study of ARO-CFB in Adult Healthy Volunteers

Role: lead

NCT05413135Phase 2Completed

Study of ARO-APOC3 in Adults With Dyslipidemia

Role: lead

NCT04998201Phase 2Completed

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Role: lead

NCT05276570Phase 1Completed

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Role: lead